NO20091243L - Titreringsskjema for bifeprunox for behandling av schizofreni og kits for anvendelse deri - Google Patents
Titreringsskjema for bifeprunox for behandling av schizofreni og kits for anvendelse deriInfo
- Publication number
- NO20091243L NO20091243L NO20091243A NO20091243A NO20091243L NO 20091243 L NO20091243 L NO 20091243L NO 20091243 A NO20091243 A NO 20091243A NO 20091243 A NO20091243 A NO 20091243A NO 20091243 L NO20091243 L NO 20091243L
- Authority
- NO
- Norway
- Prior art keywords
- bifeprunox
- treatment
- titration scheme
- schizophrenia
- kits
- Prior art date
Links
- 229950009087 bifeprunox Drugs 0.000 title abstract 3
- 238000004448 titration Methods 0.000 title abstract 3
- CYGODHVAJQTCBG-UHFFFAOYSA-N Bifeprunox Chemical compound C=12OC(=O)NC2=CC=CC=1N(CC1)CCN1CC(C=1)=CC=CC=1C1=CC=CC=C1 CYGODHVAJQTCBG-UHFFFAOYSA-N 0.000 title abstract 2
- 201000000980 schizophrenia Diseases 0.000 title 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 abstract 2
- -1 bifeprunox compound Chemical class 0.000 abstract 1
- 235000010290 biphenyl Nutrition 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000977 initiatory effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Inorganic Chemistry (AREA)
- Addiction (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84124406P | 2006-08-31 | 2006-08-31 | |
| EP06119936 | 2006-08-31 | ||
| US84149506P | 2006-09-01 | 2006-09-01 | |
| EP06120016 | 2006-09-01 | ||
| PCT/EP2007/058957 WO2008025780A1 (en) | 2006-08-31 | 2007-08-29 | Titration schedule for bifeprunox for treating schizophrenia and kits for use therein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20091243L true NO20091243L (no) | 2009-03-25 |
Family
ID=38704953
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20091243A NO20091243L (no) | 2006-08-31 | 2009-03-25 | Titreringsskjema for bifeprunox for behandling av schizofreni og kits for anvendelse deri |
Country Status (10)
| Country | Link |
|---|---|
| EP (2) | EP2059245A1 (pt) |
| JP (2) | JP2010501625A (pt) |
| KR (1) | KR20090063228A (pt) |
| AU (2) | AU2007291234A1 (pt) |
| BR (1) | BRPI0715445A2 (pt) |
| CA (2) | CA2661120A1 (pt) |
| EA (1) | EA200970239A1 (pt) |
| IL (1) | IL196867A0 (pt) |
| NO (1) | NO20091243L (pt) |
| WO (2) | WO2008025781A1 (pt) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010060742A1 (en) * | 2008-11-03 | 2010-06-03 | Solvay Pharmaceuticals B.V. | Combination of bifeprunox and an antipsychotic drug with d2/5-ht2a receptor antagonistic activity for treating cns disorders |
| WO2010070061A1 (en) * | 2008-12-19 | 2010-06-24 | Abbott Healthcare Products B.V. | Compositions, kits and methods of a titration schedule for bifeprunox compounds |
| AU2010266018B2 (en) | 2009-06-25 | 2014-01-09 | Alkermes Pharma Ireland Limited | Heterocyclic compounds for the treatment of neurological and psychological disorders |
| WO2011023796A1 (en) | 2009-08-31 | 2011-03-03 | Abbott Healthcare Products B.V. | Bifeprunox for treating addiction |
| WO2014080285A2 (en) | 2012-09-19 | 2014-05-30 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions having improved storage stability |
| CN110368360A (zh) | 2014-03-20 | 2019-10-25 | 奥克梅斯制药爱尔兰有限公司 | 具有增加的注射速度的阿立哌唑制剂 |
| WO2019173230A1 (en) | 2018-03-05 | 2019-09-12 | Alkermes Pharma Ireland Limited | Aripiprazole dosing strategy |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2271967T3 (es) | 1996-03-29 | 2007-04-16 | Duphar International Research B.V | Compuestos de piperazina y piperidina. |
| CA2310950C (en) * | 2000-04-03 | 2005-11-08 | Janssen Pharmaceutica N.V. | An efficacious dosage regiment of galantamine that reduces side effects |
| AR034206A1 (es) | 2001-02-16 | 2004-02-04 | Solvay Pharm Bv | Un procedimiento para la preparacion de mesilatos de derivados de piperazina y dichos mesilatos |
| AR045362A1 (es) * | 2003-08-18 | 2005-10-26 | Solvay Pharm Bv | Forma cristalina estable de mesilato de bifeprunox (monometansulfonato de 7-[4-([1,1- bifenil] -3- ilmetil) -1- piperazinil] - 2-(3h) -benzoxazolona |
| US7423040B2 (en) * | 2005-02-18 | 2008-09-09 | Irene Eijgendaal | Stable crystalline form of bifeprunox mesylate, dosage forms thereof and methods for using same |
| WO2007023141A1 (en) | 2005-08-22 | 2007-03-01 | Solvay Pharmaceuticals B.V. | N-oxides as prodrugs of piperazine & piperidine derivatives |
-
2007
- 2007-08-29 AU AU2007291234A patent/AU2007291234A1/en not_active Abandoned
- 2007-08-29 JP JP2009526088A patent/JP2010501625A/ja not_active Withdrawn
- 2007-08-29 EP EP07802975A patent/EP2059245A1/en not_active Withdrawn
- 2007-08-29 WO PCT/EP2007/058958 patent/WO2008025781A1/en not_active Ceased
- 2007-08-29 EA EA200970239A patent/EA200970239A1/ru unknown
- 2007-08-29 CA CA002661120A patent/CA2661120A1/en not_active Abandoned
- 2007-08-29 BR BRPI0715445-3A patent/BRPI0715445A2/pt not_active IP Right Cessation
- 2007-08-29 KR KR1020097006567A patent/KR20090063228A/ko not_active Withdrawn
- 2007-08-29 WO PCT/EP2007/058957 patent/WO2008025780A1/en not_active Ceased
- 2007-08-29 EP EP07802974A patent/EP2059244A1/en not_active Withdrawn
- 2007-08-29 CA CA002661800A patent/CA2661800A1/en not_active Abandoned
- 2007-08-29 JP JP2009526089A patent/JP2010501626A/ja not_active Withdrawn
- 2007-08-29 AU AU2007291235A patent/AU2007291235A1/en not_active Abandoned
-
2009
- 2009-02-03 IL IL196867A patent/IL196867A0/en unknown
- 2009-03-25 NO NO20091243A patent/NO20091243L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2661120A1 (en) | 2008-03-06 |
| JP2010501626A (ja) | 2010-01-21 |
| KR20090063228A (ko) | 2009-06-17 |
| AU2007291234A1 (en) | 2008-03-06 |
| JP2010501625A (ja) | 2010-01-21 |
| WO2008025781A1 (en) | 2008-03-06 |
| IL196867A0 (en) | 2009-11-18 |
| EP2059245A1 (en) | 2009-05-20 |
| BRPI0715445A2 (pt) | 2014-05-13 |
| WO2008025780A1 (en) | 2008-03-06 |
| AU2007291235A1 (en) | 2008-03-06 |
| EP2059244A1 (en) | 2009-05-20 |
| EA200970239A1 (ru) | 2009-08-28 |
| CA2661800A1 (en) | 2008-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20091243L (no) | Titreringsskjema for bifeprunox for behandling av schizofreni og kits for anvendelse deri | |
| DOP2010000165A (es) | 4-(4-ciano-2-tioaril) dihidropirimidinonas y su uso como inhibidores de la elastasa neutrofila humana | |
| NO20080675L (no) | P38-Map kinaseinhibitorer og metoder for deres anvendelse | |
| MA30652B1 (fr) | Composes organiques | |
| BRPI0417260A (pt) | derivados de azepinoindol como agentes farmacêuticos | |
| BR0310106A (pt) | Composto, processo para a produção de um composto, composição farmacêutica, uso do composto e método para o tratamento de um sujeito em sofrimento de uma condição ou doença patalógica | |
| DE50311898D1 (de) | Fredericamycin-derivate als arzneimittel zur tumorbehandlung | |
| NO20044534L (no) | Substituerte fenylacetamider og deres anvendelse som glukokinaseaktivatorer | |
| BR0313562A (pt) | derivados de indol ou benzimidazol para a modulação da ikb-cinase | |
| MA34361B1 (fr) | Dérivés de tétrahydro-pyrido-pyrimidine | |
| NO20090755L (no) | Amino-imidazoloner og deres anvendelse som et medikament for behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerering og demens | |
| ATE510841T1 (de) | Thiazoliopyrimidine und ihre verwendung als hemmer der phosphatidylinositol-3 kinase | |
| BRPI0720551A2 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, e, uso do mesmo, método para o tratamento de câncer, processos para a preparação de uma composição farmacêutica e de um composto ou de um sal farmaceuticamente aceitável do mesmo | |
| NO20011721L (no) | N-aralkylaminotetraliner som ligander for neuropeptid Y Y5- reseptoren | |
| CL2008001743A1 (es) | Uso de un compuesto derivado de quinazolina para tratar el cancer; uso del compuesto y de otro compuesto antineoplasico; compuestos derivados de quinazolina; y composicion farmaceutica que los comprende. | |
| UY28931A1 (es) | Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis | |
| GEP20125538B (en) | 2,3-dihydrobenzo(1,4) dioxin-2-ylmethyl derivatives as alpha2c antagonists for use in the treatment of peripheric and central nervous system diseases | |
| NO20083758L (no) | Nye terapautiske kombinasjoner for behandling av depresjon | |
| DE60206911D1 (de) | Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren | |
| TW200510333A (en) | Benzimidazole compounds | |
| BRPI0806789B8 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo | |
| ATE327225T1 (de) | Neue verwendung von benzothiazolderivaten | |
| NO20090266L (no) | Piperazinylderivater anvendelige i behandlingen av GPR38 receptormedierte sykdommer | |
| CL2007000595A1 (es) | Compuestos derivados de piperidina; composicion farmaceutica y uso para el tratamiento y/o profilaxis de enfermedades seleccionadas entre hipertension, insuficiencia cardiaca congestiva e insuficiencia renal entre otras. | |
| MX2008013017A (es) | Tratamiento de malignidades hematologicas con fts y un inhibidor de tirosina cinasa de bcr-abl. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |